Information Provided By:
Fly News Breaks for April 7, 2017
ISRG, BSX, MDT
Apr 7, 2017 | 06:55 EDT
Citi analyst Amit Hazan says his firm's semi-annual survey of 40 U.S. endocrinologists has come back "significantly more positive" for Medtronic (MDT). The analyst makes the stock his top pick in Medical Supplies for the rest of 2017, replacing Boston Scientific (BSX) and Intuitive Surgical (ISRG). The survey shows "significant" new shares gains for Medtronic in pumps and the CGM segment, Hazan tells investors in a research note. The analyst keeps a Buy rating on Medtronic with a $93 price target.
News For MDT;BSX;ISRG From the Last 2 Days
BSX
Apr 25, 2024 | 08:24 EDT
Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."
BSX
Apr 25, 2024 | 06:29 EDT
Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here